Table 4. COG enrollment stratified by disease type, age, and race, 2004–2015.
| Disease Type | Age (years) | Race/Ethnicity a | ||||
|---|---|---|---|---|---|---|
| White | Black | Hispanic | Asian/ Pacific Islander |
American Indian/Alaskan | ||
| SR (95% CI) b | SR (95% CI) b | SR (95% CI) b | SR (95% CI) b | SR (95% CI) b | ||
| % Enrolled | % Enrolled | % Enrolled | % Enrolled | % Enrolled | ||
| Hematologic malignancies |
Total (0 to 29) |
0.99 (0.98, 1.01) | 0.72 (0.69, 0.75) | 1.15 (1.12, 1.18) | 0.93 (0.87, 0.98) | 0.59 (0.49, 0.70) |
| 19.8% | 14.3% | 22.9% | 18.4% | 11.8% | ||
| 0 to 4 | 2.34 (2.28, 2.40) | 1.83 (1.69, 1.96) | 1.87 (1.79, 1.94) | 1.87 (1.69, 2.05) | 1.10 (0.80, 1.40) | |
| 46.6% | 36.4% | 37.2% | 37.3% | 21.9% | ||
| 5 to 9 | 2.38 (2.30, 2.46) | 1.74 (1.59, 1.90) | 2.17 (2.06, 2.27) | 1.96 (1.72, 2.2) | 1.60 (1.07, 2.13) | |
| 47.4% | 34.7% | 43.1% | 39.0% | 31.8% | ||
| 10 to 14 | 1.33 (1.28, 1.39) | 0.99 (0.89, 1.08) | 1.30 (1.21, 1.38) | 1.12 (0.94, 1.31) | 0.60 (0.32, 0.88) | |
| 26.5% | 19.6% | 25.9% | 22.4% | 12.0% | ||
| 15 to 19 | 0.98 (0.94, 1.02) | 0.86 (0.78, 0.94) | 1.17 (1.10, 1.25) | 0.94 (0.79, 1.08) | 0.35 (0.14, 0.56) | |
| 19.5% | 17.2% | 23.4% | 18.7% | 7.0% | ||
| 20 to 24 | 0.20 (0.18, 0.21) | 0.15 (0.12, 0.18) | 0.25 (0.22, 0.28) | 0.21 (0.15, 0.27) | 0.15 (0.03, 0.27) | |
| 3.9% | 3.0% | 4.9% | 4.1% | 3.0% | ||
| 25 to 29 | 0.02 (0.02, 0.03) | 0.01 (0.01, 0.02) | 0.04 (0.03, 0.05) | 0.02 (0.00, 0.03) | 0 c | |
| 0.5% | 0.3% | 0.8% | 0.3% | |||
| Solid tumors |
Total (0 to 29) |
0.17 (016, 0.17) | 0.25 (0.24, 0.27) | 0.17 (0.17, 0.18) | 0.15 (0.13, 0.17) | 0.09 (0.06, 0.11) |
| 3.3% | 5.0% | 3.5% | 3.0% | 1.7% | ||
| 0 to 4 | 1.00 (0.96, 1.03) | 0.85 (0.78, 0.93) | 0.74 (0.69, 0.80) | 0.77 (0.65, 0.89) | 0.35 (0.18, 0.52) | |
| 19.8% | 17.0% | 14.8% | 15.3% | 7.0% | ||
| 5 to 9 | 1.05 (0.98, 1.11) | 0.94 (0.82, 1.06) | 0.76 (0.66, 0.86) | 0.90 (0.65, 1.15) | 0.56 (0.17, 0.94) | |
| 20.8% | 18.7% | 15.1% | 17.9% | 11.1% | ||
| 10 to 14 | 0.47 (0.44, 0.51) | 0.50 (0.43, 0.58) | 0.36 (0.32, 0.41) | 0.35 (0.22, 0.46) | 0.28 (0.06, 0.50) | |
| 9.4% | 10.0% | 7.3% | 6.9% | 5.6% | ||
| 15 to 19 | 0.23 (0.21, 0.24) | 0.39 (0.34, 0.44) | 0.23 (0.20. 0.26) | 0.18 (0.13, 0.24) | 0.13 (0.03, 0.23) | |
| 4.5% | 7.7% | 4.6% | 3.6% | 2.7% | ||
| 20 to 24 | 0.04 (0.03, 0.04) | 0.06 (0.05, 0.08) | 0.03 (0.03, 0.04) | 0.03 (0.01, 0.04) | 0.01 (-0.01, 0.03) | |
| 0.7% | 1.2% | 0.7% | 0.6% | 0.2% | ||
| 25 to 29 | 0.01 (0.00, 0.01) | 0.01 (0.00, 0.01) | 0.00 (0.00, 0.00) | 0.01 (0.00, 0.01) | 0 c | |
| 0.1% | 0.1% | 0.0% | 0.1% | |||
| CNS tumors |
Total (0 to 29) |
0.25 (0.24, 0.26) | 0.29 (0.26, 0.33) | 0.30 (0.27, 0.32) | 0.26 (0.20, 0.31) | 0.15 (0.06, 0.24) |
| 5.0% | 5.9% | 5.9% | 5.1% | 3.0% | ||
| 0 to 4 | 0.29 (0.26, 0.32) | 0.28 (0.22, 0.35) | 0.33 (0.27, 0.39) | 0.26 (0.14, 0.37) | 0.19 (-0.02, 0.40) | |
| 5.8% | 5.7% | 6.6% | 5.1% | 3.7% | ||
| 5 to 9 | 0.42 (0.39, 0.46) | 0.50 (0.40, 0.59) | 0.44 (0.36, 0.51) | 0.36 (0.22, 0.51) | 0.24 (-0.03, 0.50) | |
| 7.9% | 9.9% | 8.7% | 7.2% | 4.7% | ||
| 10 to 14 | 0.40 (0.36, 0.44) | 0.31 (0.23, 0.39) | 0.42 (0.34, 0.51) | 0.43 (0.26, 0.61) | 0.12 (-0.11, 0.35) | |
| 7.9% | 6.2% | 8.4% | 8.6% | 2.3% | ||
| 15 to 19 | 0.31 (0.27, 0.34) | 0.40 (0.30, 0.50) | 0.34 (0.26, 0.43) | 0.29 (0.15, 0.43) | 0.26 (-0.03, 0.30) | |
| 6.1% | 8.0% | 6.9% | 5.8% | 5.2% | ||
| 20 to 24 | 0.09 (0.07, 0.11) | 0.12 (0.06, 0.18) | 0.10 (0.05, 0.15) | 0.14 (0.04, 0.24) | 0 c | |
| 1.8% | 2.4% | 2.0% | 2.8% | |||
| 25 to 29 | 0 c | 0 c | 0 c | 0.02 (-0.02, 0.05) | 0 c | |
| 0.3% | ||||||
a 2+ races and unknown race/ethnicity patients were excluded given no corresponding US SEER data available.
b Using total percent enrollment of patients 0 to 19 years old (19.9%).
c Indicates that no patients of this subgroup enrolled into COG therapeutic trials.
Abbreviations: SR, Standardized Ratio of Enrollment; CI, Confidence Interval; CNS, Central Nervous System.